Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

Authors:
Open Access
Publisher website
Google Scholar
Abstract
University of California, San Francisco researchers recently reported in Science the mutational profiling of 23 initially low-grade gliomas (LGGs) and associated recurrent tumors and profiled a subset of recurrent tumors in temozolomide-treated patients. Three key findings with potentially important clinical implications for LGG management were demonstrated: (1) LGGs and paired recurrent tumors are highly divergent and often only share a few early mutations, thus partly explaining their differential therapeutic responses; (2) mutant isocitrate dehydrogenase-1 (IDH1) may be critical for LGG formation and is a potential therapeutic target; and (3) temozolo-mide therapy may contribute to malignant transformation and affect clinical outcome.